Application Value of Accelerated Hyperfractionated Radiotherapy Combined with PD-1 Inhibitor after Induction Chemotherapy for Small Cell Lung Cancer
Objective:To analyze the application value of accelerated hyperfractionated radiotherapy combined with programmed death receptor-1(PD-1)inhibitor after induction chemotherapy in small cell lung cancer(SCLC).Method:Clinical data of 82 SCLC patients admitted to Xinyu People's Hospital from April 2021 to March 2023 were retrospectively selected,and divided into observation group(n=42)and control group(n=40)according to treatment methods.The control group received induction chemotherapy with Etoposide+Cisplatin/Carboplatin(EP)or Irinotecan+Cisplatin(IP)regimen combined with accelerated hyperfractionation radiotherapy,the observation group was combined with new PD-1 inhibitor on the basis of control group.The clinical efficacy,serum tumor markers,Karnofsky score before and after treatment,survival and adverse reactions were compared between the two groups.Result:The short-term objective response rate(ORR)in the observation group was significantly higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,serum levels of pro-gastrin releasing peptide(ProGRP),neurone-specific enolase(NSE),soluble fragment of cytokeratin-19(Cyfra21-1)and carcinoembryonic antigen(CEA)in two groups were lower than those before treatment,and those in observation group were lower than those in control group,the differences were statistically significant(P<0.05).At 1,6 and 12 months after treatment,the Karnofsky scores of the two groups were higher than those before treatment,and the Karnofsky scores of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).The progression-free survival rate and overall survival rate during the past year in the observation group were slightly higher than those in the control group,but there were no statistical significance between the two groups(P>0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Accelerated hyperfractionated radiotherapy combined with PD-1 inhibitor for induction chemotherapy in SCLC patients can significantly improve the clinical efficacy,reduce the level of tumor markers,and is safe and reliable.
万方数据
维普
